北大医药董事长被刑拘，1元入主公司尚不足一年

Core Points - The chairman and president of Beijing University Pharmaceutical, Xu Xiren, has been criminally detained and is cooperating with investigations, temporarily unable to perform his duties [2][8] - Despite this situation, the company's control has not changed, and its board operations, financial, and production management remain normal [2] Company Background - Xu Xiren acquired control of Beijing University Pharmaceutical at the end of last year for 1 yuan, taking on significant debt [4] - He became the actual controller of the company after acquiring a 22.22% stake through a series of transactions involving a debt of approximately 2.392 billion yuan [4] - The company, originally established in 1965, was listed on the Shenzhen Stock Exchange in 1997 and became part of the Ping An Group in 2022 [4] Recent Changes and Challenges - Following the change in control, the company is undergoing a rebranding process, including a name change that will remove "Beijing University" from its title [5] - A significant contract with Beijing University International Hospital is set to expire in May 2025, which is expected to reduce the company's sales revenue by approximately 600 million yuan and net profit by about 40 million yuan [5] - The company anticipates a revenue decrease of around 1.027 billion yuan starting in 2026, which would represent about 49.85% of its 2024 revenue [5] Management Changes - The company has experienced significant management turnover, including the resignation of several key executives since the change in control [6][5] - The former president, Yuan Pingdong, who contributed to the company's turnaround, resigned after nine years [6] - Recent protests by retired employees have raised concerns about the company's governance capabilities [7][8]